Effect of Human Umbilical CordMesenchymal Stem Cells on Breast Carcinoma Therapy

Thesis **Submitted for full fulfillment of M.Sc Degree**

In Medical Biochemistry

Presented by

AbeerMostafa Ali Soliman

M.B., B.Ch, Medical Biochemistry, CairoUniversity

Supervised by

Prof. Dr. Mohamed Talaat Abd El Aziz

Professor of Medical Biochemistry and Molecular Biology Faculty of Medicine CairoUniversity

Prof. Dr. Dina Sabry Abd El Fatah

Professor of Medical Biochemistryand Molecular Biology Faculty of Medicine CairoUniversity

Dr. Ayman Ahmed Hassan

Lecturer of Obstetrics and Gynecology Faculty of Medicine CairoUniversity

Medical Biochemistry and Molecular Biology Department Faculty of Medicine CairoUniversity (2014)

<u>Acknowledgment</u>

First and foremost, thanks to ALLAH, who is most beneficial and most merciful.

I had the honor to accomplish my work under the supervision of Doctor Mohamed Talaat AbdEl-Aziz Professorof Medical Biochemistry, Faculty of Medicine, Cairo University. I am really indebted to him for his unlimited support and kind encouragement during this work.

I wish to express my sincere thanks and gratitude to Doctor Dina Sabry Abd El-Fatah Professor of Medical Biochemistry, Faculty of Medicine, Cairo University for her valuable help and expert advice throughout this study.

I also wish to express my deep thanks to Doctor Ayman Ahmed Hassan Lecturer of Obstetrics and Gynecology, Faculty of Medicine, Cairo University for his help throughout this study.

I would like to express my deep thanks to all staff members and colleagues in the Medical Biochemistry Department especially .to the team of the Unit OF Biochemistry and Molecular Biology, Cairo University for their help and support.

Finally, no words can express my deep thanks and appreciation to my **family** for their continuous support and outstanding encouragement during this work.

Abstract

Background:

Breast cancer is the most common malignancy in women, accounting for 27% of all female cancers; it accounts for < 1% of all cancer cases in men. Breast cancer also is responsible for 15% of cancer deaths in women, making it the number-two cause of cancer death.

Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs), isolated from discarded extra-embryonic tissue after birth, are promising candidate source of mesenchymal stem cells (MSCs). Apart from their advantages in abundant supply, painless collection, and faster self-renewal, hUC-MSCs have shown the potencies to differentiate into a variety of cells of three germ layer; hUC-MSCssynthesize and secret a set of trophic factors and cytokines to migrate toward inflammatory tissues such as cancer tissues

Methods:

This work was divided into two parts; in vitro work which involves human breast adenocarcinoma coculturewith human Wharton jellymesenchymal stem cells and in vivo work which involved transplantation of isolated hUC-MSCs into induced experimental mice with breast adenocarcinoma. We assessed cell proliferation by MTT assay, genes expression (TLR4, NF-KB, VEGF, IL-1, IL8) byqRT-PCRboth in vivo and in vitro, the level of IL-6 and JNK by ELISA technique from in vitro cultured conditioned media.

Results:

As regard cell proliferation assay there was significant decrease in breast carcinoma groups compared to all other treated cancer groups. As regard genes expression there was significant decrease in (TLR4, NF-KB, VEGF, IL1and IL-8) genes and significant decrease in (IL-6, JNK) level which are responsible for development and progression of cancer, in breast carcinoma groups compared to all other treated cancer groups. Better results were obtained by addition of doxorubicin toMSCS in treatment of breast carcinoma.

Conclusion:

HUC-MSCS can be applied in breast carcinoma treatment, as it affects the mechanism of tumor regression through modulation of different genes and cytokines expression which are involved in tumor initiation and progression. But much better results were obtained on combination between MSCS and doxorubicin for breast cancer treatment.

Key words: breast carcinoma, Wharton jellyhMSCs,doxorubicin.

Contents

	Page
List of tables	II
List of figures	IV
List of abbreviations	VI
Introduction & Aim of the work	1
Review of literature	5
Breast Carcinoma	5
Stemcells	22
Stem Cells and Cancer	39
Materials and Methods	57
Results	82
Discussion	114
Conclusion and Recommendations	128
Summary	130
References	133
Arabic summary	

List of tables

Table	Subject	page
Table 1	TNM classification for staging of breast cancer	11
Table 2	Application of TLR in cancer thereby	51
Table 3	The cDNA master mix prepared according to	67
	the kit instructions	
Table 4	The primers for the TLR4,NF-KP,VEGF,IL-	68
	1,IL-8	
Table 5	reagents and volumes added for each sample in	69
	PCR	
Table 6	Running condition for RT-PCR	69
Table 7	Standard preparation for IL-6 measure by	74
	ELISA.	
Table 8	MTT cell proliferation assay in studied groups	85
Table 9	Comparison between the TLR4 gene expression	87
	in studied groups.	
Table 10	Comparison between the NF-KB gene	89
	expression in studied groups.	
Table 11	Comparison between VEGF gene expression in	91
	studied groups.	
Table 12	Comparison between the IL1 gene expression in	93
	studied groups.	
Table 13	Comparison between the IL8 gene expressions	95
	in studied groups.	
Table 14	Comparison between the measures of	98
	phosphorylated JNK in studied groups.	
Table 15	Comparison between Quantitative	100
	measurements of human IL6 in studied groups.	

Table 16	In vivo Comparison between the TLR4 gene	102
	expression in studied groups.	
Table 17	In vivo Comparison between the NF-kB gene	104
	expressions in studied groups.	
Table 18	In vivo Comparison in the VEGF gene	106
	expression in studied groups.	
Table 19	In vivo Comparison in the IL-1gene expression	108
	in studied groups.	
Table 20	In vivo Comparison in the IL-8 gene expression	110
	in studied groups	

List of figures

figure	subject	page
Figure 1	Anatomy of female human breast.	6
Figure 2	Embryonic stem cell	25
Figure 3	Source of hematopoitic stem cells.	28
Figure 4	Development of different types of blood cells	29
Figure 5	Source of mesenchymal stem cells.	31
Figure 6	mesenchymal stem cells.	33
Figure 7	Mechanisms of MSC and cancer interactions	38
Figure 8	Therapeutic uses of stem cells.	40
Figure 9	Toll receptor structure	45
Figure 10	TLR signaling	47
Figure 11	Morphological character of MSCs in culture	83
Figure 12	MSCs identification by FACS.	83
Figure 13	MCF-7 cells	84
Figure 14	Co-culture of hUC-MSCs and hMCF7	84
Figure 15	Comparison between the cell proliferation in	
	studied groups.	86
Figure 16	Comparison between the Quantitative RT-PCR for	
	TLR4 gene Expression in studied groups	88
Figure 17	Comparison between the Quantitative RT-PCR for	
	NF-KB gene Expression in studied groups.	90
Figure 18	Comparison between the Quantitative RT-PCR for	
	VEGF gene Expression in studied groups.	92
Figure 19	Comparison between the Quantitative RT-PCR for	
	IL1 gene Expression in studied groups	94

Figure 20	Comparison between the Quantitative RT-PCR for	
	IL8 gene Expression in studied groups.	96
Figure 21	Quantitative genes expression in	
	hMSCs+MCF+doxorubicin group and the MCF	
	group.	97
Figure 22	Comparison between the measured phosphorylated	
	JNK in studied groups.	99
Figure 23	Comparison between Quantitative measurement of	
	human IL6 the in studied groups.	101
Figure 24	In vivo Comparison between the Quantitative RT-	
	PCR for TLR4 gene Expression in studied groups.	103
Figure 25	In vivo Comparison in the Quantitative RT-PCR	
	for NF-kB gene Expression in studied groups	105
Figure 26	In vivo Comparison between the Quantitative RT-	
	PCR for VEGF gene Expression in studied	
	groups.	107
Figure 27	In vivo Comparison between the Quantitative RT-	
	PCR for IL-1 gene Expression in studied groups.	109
Figure 28	In vivo Comparison between the Quantitative RT-	
	PCR for IL-8 gene Expression in studied groups	111
Figure 29	Quantitative gens expression in the MCF (+ve)	
	Control+ hMSCs+ doxorubicin group and the	
	MCF (+ve) control (induced breast carcinoma)	
	group.	112
Figure 30	Histopathological examination	113

List of abbreviation

AC	Adriamycin
AP	alkaline phosphatase
AS	antisense
ATCC	American Type Culture Collection
ATM	The ataxia-telangiectasia mutated
AT-MSC	Adipose- derived stem cells
BM-MSC	Bone Marrow Mesenchymal Stem Cell
BR	Breast cancer
CAT	cyclophosphamide, Ara-C and topotecan
СВ	Cord blood
CD	clusters of differentiation
cDNA	Complementary DNA
CHEK2	Checkpoint kinase 2
CMF	Cyclophosphamide · Methotrexate · Fluorouracil
CPG	cytidine phosphate guanosine
CRC	Colorectal cancer
CRP	c-reactive protein
СТ	Computed tomography
DAMPs	Danger-associated molecular pattern
DCIS	Ductal carcinoma in situ
DEPC	Diethylpyrocarbonate · 1,2-Erucoyl-sn-Glycero-3-
	phosphocholine
DES	Diethylstilbestrol
DKK-1	dickkopf-1
DLI	Donor lymphocytic infusion
DMEM	Dulbecco's modified Eagle's medium

DNA	Deoxy ribonucleic acid
dNTPs	Deoxynucleotide triphosphate
ECFC.	endothelial colony-forming cells
ELISA	Enzyme linked immune sorbent assay
EPC	Endothelial progenitor cell
ER	Estrogen receptor
ERK	extracellular signal-regulated kinase
FACS	Fluorescence-activated cell sorting
FBS	fetal bovine serum
G-CSF	granulocyte colony-stimulating factor
GTC	guanidine thiocyanate
GVHD	Graft versus host disease
GVT	Graft versus tumor
Н,Е	Hematoxlin and eosin
HDC	High dose chemotherapy
HE	hematoxylin and eosin
HER2	human epidermal growth factor receptor 2).
HLA	Human leukocytic antigen
HPRI	Human Placental Ribonuclease Inhibitor
HRP	horseradish peroxidase
HSC _S	Hematopoietic stem cells
HSCT	Hematopoitic stem cell transplantation
hWJSC _S	Human Wharton jelly stem cells
IgG	Immune globulin G
IKK	I-kappa B kinase complex
IL	Interlaken
INFs	interferons
IRAK	interleukin-1 receptor-associated kinase

IRFs	Interferon regulatory factors
IRFs	interferon regulatory factors
JNKs	c-Jun N-terminal kinases
KS	Kaposi sarcoma
LC	Lung cancer
LDH	Lactate dehydrogenase
LPS	Lipopolysaccharide
LPS	Lipopolysaccharide
LRRs	Leucine-rich repeats
Mal	MyD88 adaptor-like protein
MAPKs	Mitogen-activated protein kinase
MCP-1	Monocyte chemotactic protein-i
MHC	Major histocompatibility
MKP	mitogen-activated protein kinase phosphatase-1
MMLV	Moloney murine leukemia virus
MNC	Mononuclear cell
MRI	Magnetic resonance image
MSC_S	Mesenchymal stem cells
MTOR	Mammalian target of rapamycin.
MTT	4,5-dimethylthiazol-2yl]-2,5-diphenyl-tetrazolium
	bromide
MYD88	myeloid differentiation factor 88
NEMO	NF-kappa-B essential modulator
NF-KB	Nuclear factor kappa B
NF-KP	Nuclear factor kappa -light-chain-enhancer of
	activated B cells
NK	Natural killer cells
NOS	Not otherwise specified

OC	Ovarian cancer
PAMP _S	Pathogen associated microbial
PB-MSC	Peripheral blood mesenchymal stem cells
PBS	phosphate buffer saline
PBST	Phosphate Buffered Saline (PBS) solution with the
	detergent Tween
Pdcd4	Programmed cell death 4
PET	positron emission tomography
PGN	Peptidoglycan
PI3K	Phosphoinositide 3-kinase
PI3K/AKT	Phosphoinositide-3-kinas
PL-MSC _S	Placenta derived mesenchymal stem cell
PR	Progesterone receptor
PTEN	Phosphatase and tensin homolog
RAS/MEK/ERK	Mitogen-activated protein kinase –ERK kinase
RCC	Renal cell carcinoma
RFUs	relative fluorescence units
RICT	Reduced intensity conditioning regimens
RNA	Ribo nucleic acid
RT-PCR	Reverse transcriptase polymerase chain reaction
SAPK	Stress-activated protein kinase
SCLC	Small cell lung carcinoma
SCT	Stem cell transplantation
TAK1	Transforming growth factor \$activated kinase-1
Taq	TaqMan
TICAM2	TIR domain-containing adapter molecule 2
TIRAP	TIR-associated protein
TLR	Toll like receptor

TLR	Toll like receptor
TNF-α	Tumor necrosis factor
TRAF	TNF receptor associated factor
TRAM	TRIF-related adaptor molecule
TRIF	TIR domain-containing adaptor protein-inducing
	IFN-β
UC	Umbilical cord
UCMSC	Umbilical cord mesenchymal stem cell
VACCERA	The Holding Company for Biological Products and
	Vaccines
VEGF	Vascular endothelium growth factor

Introduction & Aim of the work

Breast cancer (malignant breast neoplasm) is a type of cancer originating from breast tissue, most commonly from the inner lining of milk ducts or the lobules that supply the ducts with milk. Cancers originating from ducts are known as ductal carcinomas; those originating from lobules are known as lobular carcinomas. Breast cancer is a disease of humans and other mammals.

Human umbilical cord (UC) has been recently suggested as a valid alternative tissue for MSCs. The UC is a tissue of extraembryonic origin lying between the mother and the fetus, consisting of two arteries, one vein, intervessels connective tissue (the Wharton's jelly), and umbilical epithelium.

The UC is normally discarded after birth. Therefore, UC collection does not require any invasive procedure nor implies major ethical concerns. MSCs have been isolated from all compartments of the umbilical cord tissue, namely, the umbilical vein endothelium and subendothelium and the Wharton's jelly. Within Wharton's jelly, MSCs have been isolated from three regions: the perivascular zone (UC perivascular cells), the intervascular zone, and the subamnion.

Fong et al., 2012, reported that BM-MSCs have been used for various cell-based therapies but have the limitations of painful harvest, morbidity, and risk of infection to the patient. This prompted researchers to explore the use of human umbilical cord Wharton's jelly MSCs (hWJSCs) and its conditioned medium (hWJSC-CM) because hWJSCs can be harvested in abundance painlessly, are proliferative, hypoimmunogenic, and secrete a variety of unique proteins. They proposed that cord blood banks freeze autologous hWJSCs and

umbilical cord blood (UCB) from the same umbilical cord at the same time for the patient for future cell-based therapies.

Wharton's jelly-derived MSCs have shown multilineage capability along with immune regulatory properties. It has been shown that a single injection of MHC mismatched unactivated human UC-MSCs did not induce a detectable immune response; therefore, they can be tolerated in allogeneic transplantation.

Advantage of UCMSCs

- Widespread availability.
- Absence of donor risk.
- Low risk of transmissible infectious diseases.
- Decreased graft-versus-host disease.
- Increased precursors of immune effector cells.

Toll-like receptors, a mammalian homologue of the drosophila toll protein, are the best-characterized family of pattern-recognition receptors (PRRs), which sense foreign material, so called pathogen-associated molecular patterns (PAMPs), derived from bacteria or virus. After activation of TLRs with their ligands either directly or with help of accessory proteins such as CD14 and MD2 (in case of TLR2/4), cells evoke inflammatory response, coordinate the immune system in the whole organism, and finally protect the host from spreading massive pathogen after infection.

It has been known that TLR expression in many tumors or cell lines was up-regulated. Also, in some tumor models, polymorphisms of TLR2 and 4have been known to influence the risk of cancer, implicating that genetic variation in specific TLR may be associated with specific tumor progression. TLR4 has been known as indicative molecule for detection of predisposition to a cancer.